

Index

A

Abdelatif, O.M., 46
Aberrant crypt foci (ACF), 5
Aberrant DNA methylation pathway, 147
Achalasia, 55
Adenocarcinoma
 CRC, 143
 esophageal (*see* Esophageal adenocarcinoma (EAC))
Adenomatous polyposis coli (ACP), 150
Adhesion, CEA, 252
Adoptive immunotherapies, gastric carcinoma, 76
Affinitor, 205, 206
Alternative lengthening of telomeres (ALT), 12
Anal canal cancer
 anatomy, anal canal, 141–142, 155–156
 anorectal melanoma, 160–161
 carcinoid and neuroendocrine tumors, 161–162
 GIST, 161
 histological subtypes
 EGFR, 159, 160
 HIV, 158–159
 HPV, 156–158
 squamous cell carcinoma, 156
 lymphoma, 162
Anal intraepithelial neoplasia (AIN), 156
Anorectal melanoma, 160–161
Antisecretory therapy, 199
Antolovic, D., 232
Alpha cell tumors. *See* Glucagonomas
Attenuated familial adenomatous polyposis, 124
Auwera, I., 235

B

Bacani, J.T., 100
Balasubramanian, P., 233
*Bam*HIA rightward transcripts (BARTs), 73
Barker, N., 69
Barrett's metaplasia (BM), 5
 acid and bile, 43
 CDKN2 (p16), 47
 CDX, 43–44
 cyclin D1, 44
 cyclooxygenase-2, 44
 cytokines, 45–46
 description, 43
 DNA
 methylation, 46
 ploidy abnormalities, 48
 epidermal growth factor receptor, 45
 Her-2/erbB-2/neu, 45

 microRNAs, 48
 microsatellite and chromosomal instability, 45
 multiple molecular abnormalities, 48
 MYC, 46
 RAS and RAF, 46–47
 TP53, 47–48
Benzo-a-pyrene, 54
Bernal, C., 238
Beta cell tumors. *See* Insulinomas
Biedermann, K., 95
Bile acids, 43
Bockhorn, M., 230
Boterberg, T., 97
BRAF mutations, 153

C

CA 19-9, 259–261
CA 50, 260, 261
CA 72-4, 260, 261
CA 125, 260, 261
CA 242, 260, 261
Cadherin switching, in EMT, 217
Calin, G.A., 18
Cancer-associated genomic regions (CAGRs), 19
Capelle, L.G., 100
Carcinoembryonic antigen (CEA)
 assays, 254
 biochemistry, 251–252
 in colon cancer
 chemotherapy, 257
 National Academy of Clinical Biochemistry Laboratory
 Medicine Practice Guidelines, 254, 255
 planning therapy, staging and evaluating
 prognosis, 255
 postoperative surveillance, 255–256
 screening, 254
 CTC, 253
 in esophageal cancer, 258
 expression and regulation, 252
 false-negative results, 259
 false-positive results, 258–259
 functional aspects, 252–253
 in gastric cancer, 257–258
 imaging, 253
 in non-GI tumors, 258
 target for therapy, 253
CDH1 gene
 CDH1+/-mice, 96
 cleft lip with or without cleft palate, 94
 genetic testing, criteria for, 84

- CDH1* gene (*cont.*)
 germline alterations, 89–92
 allelic imbalance, 88, 93–94
 clinical settings and geographic origins, 88
 frequency, site and type, 88
 hereditary lobular breast cancer, 94
 missense mutation, 85, 97
 pathology
 macroscopy, 85
 microscopy, 85–87
 second-hit inactivating mechanisms, 95–96
 structure, 83, 84
 and tumor cell survival, 99
- CDKN2A/p16, 222
- CEA. *See* Carcinoembryonic antigen (CEA)
- CellSearch method, 232
- Lara, 233
- Chen, J.D., 95
- Chen, X.-M., 237
- Chi, P., 185
- Chromosomal instability, 15–16
 Barrett's metaplasia and esophageal adenocarcinoma, 45
 CRC
 pathway in, 146–147
 sporadic, 131–132
- Circulating tumor cells (CTC)
 biology, 230–231
 collection, 232
 colon cancer, 238–239
 EMT, 218
 and esophageal cancer, 235–236
 gastric cancer, 237
 historical background, 230
 methods of analysis, 233
 red cell lysis
 flow cytometric/cytometric methods, 232
 negative immunoselection, 233
 positive immunoselection, 232
 size selection, 232
 terminology, 229–230
- Circulating tumor nucleic acids (CNA)
 biology, 234–235
 colon cancer, 239–240
 esophageal cancer
 cfDNA, 236
 circulating miRNA, 237
 and methylation, 236–237
 gastric cancer, 238
 history, 233–234
 methods, 235
 minimal residual disease, 241
 screening populations, 241
- Colon cancer
 CEA
 chemotherapy, 257
 National Academy of Clinical Biochemistry Laboratory
 Medicine Practice Guidelines, 254, 255
 planning therapy, staging and evaluating prognosis, 255
 postoperative surveillance, 255–256
 screening, 254
 CNA, 239–240
 CTC, 238–239
 promising markers, 261
- Colorectal cancer (CRC)
 CA 19-9, 259
 histological subtypes
 adenocarcinoma, 143
 medullary carcinoma, 144
 mucinous and signet cell tumors, 143–144
 squamous cell carcinoma, 144
- molecular markers
 adenomatous polyposis coli, 150
 BRAF, 153
 EGFR, 151–152
 KRAS, 152–153
 microarray assays, 155
 PI3KCA/PTEN, 154
 thymidylate synthase, 155
 TP53, 150–151
 VEGF, 154
- molecular pathways
 aberrant DNA methylation pathway, 147
 chromosomal instability pathway, 146–147
 microsatellite instability pathway, 147
- neoplasms, 155
 pathology, 142–143
 prognostic factors, 148–150
 staging, 145
- Cowden syndrome, 103
- CpG island methylator phenotype (CIMP), 17
- c-Src kinase activation, 96
- Cunningham, M.P., 151
- Cushing's syndrome, 202
- Cyclin D1, 57
- Cyclooxygenase-2, 44
- Cytotoxin-associated antigen A (CagA) proteins, 70
- D**
- Delta cell tumors. *See* Gastrinoma; Zollinger Ellison syndrome (ZES)
- Dietary zinc deficiency, 56
- Disseminated tumor cells (DTC), 229
- E**
- Early-onset gastric cancer (EOGC)
CDH1 germline sequence variants, 100, 101
 clinical and pathological features, 99–100
 definition, 99
- E-cadherin. *See also CDH1* gene
 expression, 75
 structure, 83, 84
- Eicosanoids, 13
- Endometrial cancer, 118–120
- Epidermal growth factor receptor (EGFR)
 anal canal cancer, 159, 160
 CRC, 151–152
 ESCC, 57
 gastric carcinoma, 75
 IBD, 176
- Epithelial to mesenchymal transition (EMT)
 cadherin switching, 217
 cell signaling pathways, 217–218
 circulating tumor cells, 218
 importance of, 215–216
 markers and regulatory mechanisms, 216
 senescence and cancer stem cell theory, 218
 transcription factor regulations, 217–218
- Epstein-Barr virus
 clinicopathological characteristics, 73–74
 molecular pathways of, 74–75
 role in gastric cancer, 74
 virology and molecular biology, 73
- Esophageal adenocarcinoma (EAC)
 acid and bile, 43

- CDKN2 (p16), 47
 CDX, 43–44
 cyclooxygenase-2, 44
 cytokines, 45–46
 DNA
 methylation, 46
 ploidy abnormalities, 48
 epidermal growth factor receptor, 45
 Her-2/erbB-2/neu, 45
 incidence of, 43
 microRNAs, 48
 microsatellite and chromosomal instability, 45
 multiple molecular abnormalities, 48
 MYC, 46
 RAS and RAF, 46–47
 TP53, 47–48
- Esophageal cancer**
 CEA, 258
 and circulating tumor cells, 235–236
 circulating tumor nucleic acids
 cfDNA, 236
 circulating miRNA, 237
 and methylation, 236–237
 promising markers, 261–263
- Esophageal cancer belt**, 53
- Esophageal squamous cell carcinoma (ESCC)**
 dietary zinc deficiency, 56
 epidemiology, 53
 fruits and vegetables, low intake of, 55–56
 habits
 alcohol consumption, 54–55
 tobacco smoke, 53–54
 infectious agents, 55
 molecular alterations in
 animal models, 59
 cadherins and catenins, 58
 cyclin D1, 57
 EGFR, 57
 Krüppel-like factors, 58
 MAPK signaling, 57
 microRNAs, 58–59
 p16, 56
 p53, 56
 retinoic acid and receptors, 57–58
 TGF- β signaling, 57
 Wnt/ β -catenin signaling, 58
 predisposing conditions, 55
 prevention of, 59–60
 progressive sequence, 53, 54
 risk factors, 53
- Exon 9 mutations, 183
- F**
- Familial adenomatous polyposis (FAP)**, 102
 clinical features, 122–124
 genetic and molecular features, 124
 molecular diagnosis, 124–125
 pathology and natural history, 122–124
- Fearon, E.R., 131, 146, 150
 Feinberg, A.P., 16
 Ferguson, H.R., 44
 Fleischhacker, M., 234
 Fu, D.X., 76
 Fukayama, M., 74
- G**
- Gardner syndrome**, 124
- Gastric carcinoma (GC)**
 biomarker development, 68
 CEA, 257–285
 classifications of, 67–68
 CNA, 238
 CTC, 237
 epigenetic gene regulation, alterations of, 72
Epstein–Barr virus
 clinicopathological characteristics, 73–74
 molecular pathways of, 74–75
 role in GC, 74
 virology and molecular biology, 73
 extra-colonic neoplasia, 120
 gene expression changes, 72
Helicobacter pylori
 chronic nature, 68
 gastritis, 68–69
 infection, 68
 molecular mechanisms, 70
 stem cells in, 69–70
 susceptibility to, 70
 virulence factors, 70
 microRNAs, 72–73
 mutations in, 70–72
 personalized cancer therapies
 anti-angiogenic agents, 76
 cell surface receptor inhibitors, 75
 therapeutic approaches for, 76
 promising markers, 261–263
 treatment, 75
- Gastrinoma**
 diagnosis, 203
 epidemiology, 194
 histopathology of, 194, 195
 history and clinical presentation, 198–201
 surgical management, 203–205
- Gastrointestinal cancers**
 colon cancer
 DNA mismatch repair defects and microsatellite instability, 35–36
 EGFR signaling pathways, 36–37
 molecular testing, CRC targeted therapies, 37–39
 gastric and gastroesophageal cancers, 33–35
- Gastrointestinal carcinogenesis**
 aberrant crypt foci, 5
 Barrett's esophagus, 5
 biological factors
 carcinogen exposure, 8
 heredity, 7
 inflammatory microenvironment, 8–9
 sporadic carcinogenesis, 7–8
 cancer cells, stem cells and cancer stem cells, 17–18
 colon cancer, 3, 4
 evolutionary processes, in neoplastic transformation, 6
 gene mutations, 3
 and genetic instability
 base excision repair, 16
 chromosomal instability, 15–16
 epigenetic modification, 16–17
 microsatellite instability, 13–15
 hallmarks of, 6
 immunity to growth-inhibitory signals, 10–11

- Gastrointestinal carcinogenesis (*cont.*)
 inflammatory microenvironment, 13
 limitless replication potential, 11–12
 and microRNAs, 18–20
 self-sufficiency, in growth signals, 9
 sustained angiogenesis, 12–13
- Gastrointestinal stromal tumors (GISTs)
 anal canal cancer, 161
 biologic behavior of, 181
 clinicopathological characteristics, 186–187
 gene expression profiles, 186–187
 histopathology, 181, 182
 histopathology of, 181, 182
 immunohistochemical detection, KIT, 187
 KIT mutations, 186
 oncogenesis
 ETV1, 184–185
 KIT and PDGFRA-targeted therapy, 185–186
 KIT mutations, 182–184
 PDGFRA mutations, 183–184
 primary mutations, 182, 183
 PDGFRA mutations, 186
 tumor syndromes, 187
- Gervaz, P., 158
 Ghadimi, B.M., 155
 Giardiello, F.M., 103
 Glucagonomas
 history and clinical presentation, 196–197
 surgical management, 205
 Glutathione peroxidase-3 (GPx3), 46
 Guilford, P., 83, 99
- H**
 Hanahan, D., 6, 9
 Hardingham, J.E., 239
 Hayflick Limit, 11
Helicobacter pylori
 ESCC, 55
 gastric carcinoma
 chronic nature, 68
 gastritis, 68–69
 infection, 68
 molecular mechanisms, 70
 stem cells in, 69–70
 susceptibility to, 70
 virulence factors, 70
- He, Q., 240
 Hereditary diffuse gastric cancer (HDGC)
 animal models, 96–98
 cell culture models, 96–98
 clinical criteria, 84
 Cowden syndrome, 103
 definition, 83
 EOGC (*see* Early-onset gastric cancer (EOGC))
 familial adenomatous polyposis, 102
 genetic counseling, 84–85
 genetic susceptibility
 CASP10, 94
 CDH1-associated syndromes, 94
 CDH1 germline alterations, 87–94
 DSG2, 95
 HPP1, 94
 MET, 95
 RUNX3 and SMAD4, 94
 Li–Fraumeni syndrome, 102
 Lynch syndrome, 100, 102
 molecular pathology
 CDH1 second-hit inactivating mechanisms, 95–96
 CD44 overexpression, 96
 c-Src kinase activation, 96
 pathology
 macroscopy, 85
 microscopy, 85–87
 Peutz–Jeghers syndrome, 103
 screening, 84–85
 treatment
 potential molecular targets, 98–99
 prophylactic gastrectomy, 98
- Hereditary GIST tumor syndromes, 187
 Hereditary non-polyposis colorectal cancer–Lynch syndrome (HNPCC/LS)
 clinical features, 109, 110
 clinical management, 121–122
 extra-colonic neoplasia
 endometrial cancer, 118–120
 gastric cancer, 120
 ovarian cancer, 119–120
 pancreatobiliary carcinoma, 120
 small intestinal carcinoma, 120–121
 molecular mechanisms and progression, 112–114
 molecular testing
 constitutional germline mutations, 117
 CRC for dMMR, 117–118
 dMMR in adenomas, 117
 MSI DNA test, 115–117
 pathologic features, 111–112
- HER-2/neu oncogene amplification, 45
 He, Y., 154
 Hirota, S., 181
 Hoffmann, A.C., 236
 Human epidermal growth factor receptor 2 (HER2), 33–35
 Human papilloma virus (HPV)
 anal canal cancer, 156–158
 ESCC, 55
 Humar, B., 96
 Hundt, S., 254
 Hu, Y., 45
 Hyperplastic polyposis gene 1 (HPP1), methylation, 176
- I**
 Ikoma, D., 237
 Inflammatory bowel diseases (IBD)
 EGFR pathway, 176
 epigenetic abnormalities, 175–176
 genomic alterations and mutagenesis, 173–175
 microRNAs, 177
 pathologic features, 173
- Insulinomas
 clinical presentation, 197–198
 diagnosis of, 198
 epidemiology, 194
 history, 197–198
 surgical management, 203
- International Gastric Cancer Linkage Consortium (IGCLC), 84
 Intestinal metaplasia, 44
 Isolated tumor cells (ITC), 229–230
 Issa, J.P., 175
 Ito, H., 236

- J**
 Jahr, S., 234
- K**
 Kaganoi, J., 236
 Kang, G.H., 74
 Karapetis, C.S., 36
 Kaurah, P., 85
 Kim, I.J., 155
 Kim, I.-J., 95
 Kita, Y., 237
 Knudson, A.G., 10
 Koprowski, H., 259
 KRAS
 CRC, 152–153
 pancreatic cancer metastasis, 222
 Krukenberg tumors, 214
 Krüppel-like factors (KLF), 58
- L**
 Lara, 233
 Lauren classification, gastric carcinoma, 67
 Leedham, S.J., 47
 Lee, J.H., 95
 Lee, R.C., 18
 Leite, M., 100
 Leung, S.Y., 74
 Lewis, F.R., 98
 Li–Fraumeni syndrome (LFS), 102
 Li, J., 236, 240
 Linear progression model, 218
 Li, S., 151
 Liu, W., 264
 Liver transplantation, 205
 Lobular breast cancer, 94
 Loss of heterozygosity (LOH), 10
 Low, P.S., 232
 Luo, J., 238
 Lynch syndrome, 100, 102
- M**
 Maley, C.C., 47
 MAPK signaling, in ESCC, 57
 Matrilysin, 220
 Matsusaka, S., 237
 Mazur, M.T., 181
 Medullary carcinoma, 144
 Metastasis
 cell heterogeneity, 213–214
 colorectal cancer (*see* Metastatic colorectal cancer)
 dissemination timing, 218–219
 EMT
 cadherin switching, 217
 cell signaling pathways, 217–218
 circulating tumor cells, 218
 importance of, 215–216
 markers and regulatory mechanisms, 216
 senescence and cancer stem cell theory, 218
 transcription factor regulations, 217–218
 genetic changes, 214–216
 pancreatic cancer, 221–223
 tumor microenvironment, 213–214
 Metastatic colorectal cancer
 metastases, detection of, 220–221
 therapeutic targeting of, 221
 tissue destruction and invasion enzymes, 220
 MicroRNAs
 ESCC, 58–59
 gastric carcinoma, 72–73
 and gastrointestinal carcinogenesis, 18–20
 IBD, 177
 Microsatellite instability (MSI), 13–15
 and DNA mismatch repair defects, 35–36
 DNA test, 115–117
 pathway in CRC, 147
 Mikami, T., 176
 Miller, M.C., 238
 Mimori, K., 237
 Mismatch repair (MMR) multimer, 14
 Missense mutations, 11
 Model, F., 239
 Mucinous carcinoma, 143–144
 Muir-Torre syndrome (MTS), 121
 MUTYH-associated polyposis, 125
- N**
 Nakayama, G., 239
 Nakayama, H., 239
 Navin, N., 231
 Negative immunoselection, 233
 Neuroendocrine tumors (NET)
 American Joint Committee on Cancer, staging classification, 196, 197
 chemotherapy, 205
 epidemiology, 194
 European Neuroendocrine Tumors Society, staging classification, 196, 197
 grading system, 195, 196
 histopathology of, 194, 195
 history and clinical presentation
 gastrinoma, 198–201
 glucagonomas, 196–197
 GRFomas, 202
 insulinomas, 197–198
 neurotensinomas and ACTHomas, 202
 PPoma, 202
 somatostatinomas, 202
 Verner–Morrison syndrome, 200–201
 Zollinger–Ellison syndrome, 198–201
 localization and diagnosis, 203
 nomenclature of, 193–194
 surgical management
 gastrinoma, 203–205
 glucagonomas/PPomas/somatostatinomas, 205
 insulinoma, 203
 liver transplantation, 205
 Nonhereditary GIST syndrome, 187
- O**
 Ojima, H., 74
 Okugawa, K., 76
 Oлару, A.V., 177
 Oliveira, C., 85, 95
 Ovarian cancer, 119–120

P

Paget's hypothesis, 214
 Palefsky, J.M., 158
 Pancreatic polypeptide-secreting tumors of pancreas (PPoma), 202, 205
 Pancreatobiliary carcinoma, 120
 Parallel progression model, 219
 Passaro, E., 203
 Peach, G., 239
 Pediatric GISTs, 187
 Peutz–Jeghers syndrome (PJS), 103
 Pinheiro, H., 93
 Polyposis syndromes, gastrointestinal tract, 110
 characterization, 122
 familial adenomatous polyposis
 clinical features, 122–124
 genetic and molecular features, 124
 molecular diagnosis, 124–125
 pathology and natural history, 122–124
 MUTYH-associated polyposis, 125
 Popat, S., 148
 Positive immunoselection, 232
 PPoma. *See* Pancreatic polypeptide-secreting tumors of pancreas (PPoma)
 Prophylactic gastrectomy, 98
 Proto-oncogenes, 9

R

Rahbari, N.N., 238
 Red cell lysis, 232–233
 Reprimo, 46
 Ribic, C.M., 148
 Rogers, W.M., 86
 Roock, W., 37

S

Sabbioni, S., 239
 Sargent, D.J., 148
 Sebaceous adenoma, 121
 Seed and soil theory, 213
 Sergeant, G., 238
 Serological markers, digestive tract cancers
 CA 19-9, 259–261
 CEA
 assays, 254
 biochemistry, 251–252
 in colon cancer, 254–257
 CTC, 253
 in esophageal cancer, 258
 expression and regulation, 252
 false-negative results, 259
 false-positive results, 258–259
 functional aspects, 252–253
 in gastric cancer, 257–258
 imaging, 253
 in non-GI tumors, 258
 target for therapy, 253
 clinical applications, 249–251
 promising biomarkers, 261–263
 proteomic approaches, GI tumor markers, 263–264
 serum markers, 249
 Signet cell carcinoma, 86, 143–144

Sleeper cells, 231
 Sleepwalking cells, 231
 Small intestinal carcinoma, 120–121
 Smirnov, D.A., 233
 Somatostatinomas
 history and clinical presentation, 202
 surgical management, 205
 Sommerer, F., 47
 Sporadic colorectal cancers
 APC/B-catenin alterations, 132
 chromosome 18q loss, 132–133
 DNA
 methylator pathway, 133–134
 mismatch repair pathway, 134–136
 KRAS and BRAF, 133
 molecular markers, 136–137
 p53 gene alterations, 132
 phosphatidylinositol 3 kinase mutations, 133
 Sporadic GISTs, 186–187
 Sporadic small intestinal carcinomas, 137
 Squamous cell carcinoma
 CRC, 144
 esophagus (*see* Esophageal squamous cell carcinoma (ESCC))
 Stoecklein, N.H., 235
 Suriano, G., 100
 Sweet syndrome. *See* Glucagonomas

T

Takeshita, H., 236
 Tan, I.B., 72
 Telomerase reverse transcriptase (TERT), 12
 Telomere crisis, 12
 Thrombospondin 1 (THBS1), 12
 Thymidylate synthase (TS), 155
 TP53
 Barrett's metaplasia, 47–48
 CRC, 150–151
 esophageal adenocarcinoma, 47–48
 pancreatic cancer metastasis, 222
 ulcerative colitis, 175
 Trastuzumab, 34
 Tsujitara, M., 238
 Tumor dormancy, 231
 Turcot syndrome, 124
 Tylosis, 55

U

Uhr, 233
 Ulcerative colitis (UC), 8–9, 173. *See also* Inflammatory bowel diseases (IBD)

V

Vacuolating cytotoxin (VacA), 70
 Varmus, H., 219
 Verner–Morrison syndrome (VIPomas), 200–201
 Vogelstein, B., 16, 131, 146, 147, 150, 152, 218

W

Walch, A., 45
 Wallner, M., 239

Walther, A., 147

Wang, K., 71

Weinberg, R.A., 6, 9

Wnt/ β -catenin signaling, 58

Wnt inhibitory factor-1 (WIF-1), 46

Wong, S.C., 239

X

Xie, L., 238

Z

Zhou, H., 238

Ziegler, A., 234

Zlobec, I., 154

Zollinger Ellison syndrome (ZES)

 diagnosis of, 198–200

 epidemiology, 194

 hypertrophic mucosa and hyperplastic parietal cells, 198, 199

 Kaplan–Meier results, 201

Zombie cells, 231

Zou, H.-Z., 239, 240